Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Effect of L. crispatus M247 Administration on Pregnancy Out-comes in Women Undergoing IVF: a Controlled, Retrospective, Observational and Open-label Study

Francesco Di Pierro
* ORCID logo ,
Francesco Sinatra
,
Maddalena Cester
,
Lucia Da Ros
,
Mara Pistolato
,
Vania Da Parè
,
Laura Fabbro
,
Daniela Maccari
,
Silvia Dotto
,
Sara Sossai
,
Gemma Fabozzi
,
Alexander Bertuccioli
ORCID logo ,
Massimiliano Cazzaniga
,
Martino Recchia
,
Nicola Zerbinati
,
Luigina Guasti
,
Andrea Baffoni
Version 1 : Received: 3 October 2023 / Approved: 4 October 2023 / Online: 4 October 2023 (09:32:29 CEST)

A peer-reviewed article of this Preprint also exists.

Di Pierro, F.; Sinatra, F.; Cester, M.; Da Ros, L.; Pistolato, M.; Da Parè, V.; Fabbro, L.; Maccari, D.; Dotto, S.; Sossai, S.; Fabozzi, G.; Bertuccioli, A.; Cazzaniga, M.; Recchia, M.; Zerbinati, N.; Guasti, L.; Baffoni, A. Effect of L. crispatus M247 Administration on Pregnancy Outcomes in Women Undergoing IVF: A Controlled, Retrospective, Observational, and Open-Label Study. Microorganisms 2023, 11, 2796. Di Pierro, F.; Sinatra, F.; Cester, M.; Da Ros, L.; Pistolato, M.; Da Parè, V.; Fabbro, L.; Maccari, D.; Dotto, S.; Sossai, S.; Fabozzi, G.; Bertuccioli, A.; Cazzaniga, M.; Recchia, M.; Zerbinati, N.; Guasti, L.; Baffoni, A. Effect of L. crispatus M247 Administration on Pregnancy Outcomes in Women Undergoing IVF: A Controlled, Retrospective, Observational, and Open-Label Study. Microorganisms 2023, 11, 2796.

Abstract

Aim of our study was to retrospectively evaluate whether the oral administration of L. crispatus (M247) could increase pregnancy and live birth rates in women undergoing assisted reproductive technology procedures. Enrolled women (N=160) were divided into two groups: treated (N=80) or untreated (N=80) with the probiotic strain. The odds ratio for a treated woman to get a positive pregnancy test (PPT) was 1.56. In women aged 30–40 years, M247 increased the probability of a PPT in correlation with the progressive rise in BMI, reaching 47% (35% in controls) with a BMI of 35 (odds ratio: 2.00). The CAID statistics showed that in a woman of the blastocyst subgroup, below 43 years, with a BMI over 18.6, treatment with M247 increased the chance of a PPT from 28.4% to 44.5% (odds ratio: 2.08; p<0.05). Considering live births, rate of probiotic group was 12.5% versus 7.5% (odds ratio=1.76). Considering only the blastocyst subgroup, the treatment increased the number of live births by 200% (odds ratio: 3.64; p=0.05). As confirmed also by statistical indices like NNT, NNH and LHH, the use of M247 demonstrated a risk-benefit ratio to the full advantage of the benefits.

Keywords

vaginal microbiota; D3-embryos; D5-blastocysts; ICSI; FIVET; ART

Subject

Medicine and Pharmacology, Obstetrics and Gynaecology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF Download Supplementary

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Supplementary Files Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.